Biolase (BIOL)
(Delayed Data from NSDQ)
$0.18 USD
+0.01 (4.88%)
Updated May 8, 2024 04:00 PM ET
After-Market: $0.17 -0.01 (-3.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIOL 0.18 +0.01(4.88%)
Will BIOL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BIOL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOL
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
BIOL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BIOL
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Biolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
12 Health Care Stocks Moving In Friday's Intraday Session